NZ579566A - Modified fgf-21 polypeptides and their uses - Google Patents
Modified fgf-21 polypeptides and their usesInfo
- Publication number
- NZ579566A NZ579566A NZ579566A NZ57956608A NZ579566A NZ 579566 A NZ579566 A NZ 579566A NZ 579566 A NZ579566 A NZ 579566A NZ 57956608 A NZ57956608 A NZ 57956608A NZ 579566 A NZ579566 A NZ 579566A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- naturally encoded
- encoded amino
- polypeptides
- acid
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 235000004554 glutamine Nutrition 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 abstract 1
- 235000016491 selenocysteine Nutrition 0.000 abstract 1
- 229940055619 selenocysteine Drugs 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Provided is a modified human FGF-21 polypeptide comprising a non-naturally encoded amino acid, wherein the non-naturally encoded amino acid has a structure attached to the amino terminal which is any substituent other than a side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, pyrrolysine, or selenocysteine, and wherein the non-naturally encoded amino acid is substituted at a position selected from the group consisting of residues 72, 77, 86, 87, 91, 104, 108, 110, 126, 131, and 146.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
| NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
| PCT/US2008/057563 WO2008121563A2 (en) | 2007-03-30 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ579566A true NZ579566A (en) | 2013-01-25 |
Family
ID=48570579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ579566A NZ579566A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
| NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602702A NZ602702A (en) | 2008-03-19 | 2008-03-19 | Modified fgf-21 polypeptides and their uses |
Country Status (1)
| Country | Link |
|---|---|
| NZ (2) | NZ579566A (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597666A3 (en) | 2011-07-01 | 2020-04-22 | NGM Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| ES2828505T3 (en) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Compositions and methods for the treatment of metabolic disorders and diseases |
| PL2938740T3 (en) | 2012-12-27 | 2022-07-11 | Ngm Biopharmaceuticals, Inc. | Chimeric fgf19 peptides for use in treating bile acid disorders |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| KR102178945B1 (en) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Cancer models and associated methods |
| SI3097122T1 (en) | 2014-01-24 | 2020-07-31 | Ngm Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| CA2951153A1 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| UA123763C2 (en) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | PHARMACEUTICAL COMPOSITION FOR CONTROL OR TREATMENT OF FGF19 DISEASE OR DISORDER |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
-
2008
- 2008-03-19 NZ NZ579566A patent/NZ579566A/en unknown
- 2008-03-19 NZ NZ602702A patent/NZ602702A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ602702A (en) | 2014-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ579566A (en) | Modified fgf-21 polypeptides and their uses | |
| TW200509899A (en) | Amino acid composition and supplemental solution | |
| AR086866A1 (en) | DERIVATIVES OF OXINTOMODULIN AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM FOR THE TREATMENT OF OBESITY | |
| CA2817102A1 (en) | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | |
| AR086969A1 (en) | CONJUGATE UNDERSTANDING OXONTOMODULIN AND A FRAGMENT OF IMMUNOGLOBULIN, AND ITS USE | |
| AR105485A1 (en) | DERIVATIVE OF GLUCAGÓN AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME | |
| AR072009A1 (en) | MUTANTS OF THE GROWTH FACTOR OF FGF21 FIBROBLASTS AND USES OF THE SAME | |
| IL187188A0 (en) | Improved human interferon molecules and their uses | |
| WO2007133642A8 (en) | Sport drink containing amino acids and carbohydrates | |
| TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| UA103015C2 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| RU2011154243A (en) | CELLULAR OPTIONS WITH IMPROVED EXPRESSION, ACTIVITY AND / OR STABILITY AND THEIR APPLICATION | |
| ES2273447T3 (en) | INSECT RESISTANT TRANSGEN PLANTS AND PROCEDURES TO IMPROVE INSECT ACTIVITY. | |
| JP2006525288A5 (en) | ||
| CA3010982A1 (en) | Alpha chain of the high-affinity ige receptor (fceria) | |
| MX345513B (en) | Polypeptide. | |
| NZ600363A (en) | Modified porcine somatotropin polypeptides and their uses | |
| MX364911B (en) | Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role. | |
| NZ736642A (en) | Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders | |
| RU2015146739A (en) | COMPLEXES TYPE SUGARIDE CHAIN-POLIPEPTIDE | |
| JP2014519526A5 (en) | ||
| MXPA06014393A (en) | Oligomeric peptides and their use for the treatment of hiv infections. | |
| IN2015DN03883A (en) | ||
| DE60230621D1 (en) | EDIBLE BZW. DRINKABLE AS WELL AS MEDICALLY USE AMINO ACID COMPOSITION INCREASING BODY TEMPERATURE | |
| GEP20115196B (en) | Neublastin variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2015 BY FB RICE Effective date: 20130612 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2018 BY CPA GLOBAL Effective date: 20140903 Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 MAR 2021 BY CPA GLOBAL Effective date: 20140906 Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 19 MAR 2028 BY CPA GLOBAL Effective date: 20140908 |